Company Of The Day: Roche Holdings

October 19th, 2022 by Trefis Team
-7.11%
Downside
27.49
Market
25.54
Trefis
NWSA: News logo
NWSA
News

What?

Roche Holdings (OTCMKTS: RHHBY) Q3 2022 revenue declined 6% to CHF 14.74 billion ($14.8 billion).

Why?

Relevant Articles
  1. What’s Next For UPS Stock After A Dismal Q2?
  2. What’s Next For Textron Stock After A 5% Fall In A Week?
  3. Should You Pick RTX Corp Stock At $125 After 10% Gains In A Week?
  4. Down 23% This Year, Will Starbucks’ Stock Recover Following Q3 Results?
  5. Down 14% YTD, What Lies Ahead For McDonald’s Stock Following Q2 Earnings?
  6. Meta Platforms Stock Is Up Twice As Much As S&P500, What To Expect From Q2 Results?

A decline in demand for Covid-19 diagnostics and treatments outweighed the gains that the company made with its hemophilia and multiple sclerosis drugs.

So What?

Roche stock was down by almost 1.5% in early trading on Tuesday although it recovered later in the day.

See Our Complete Analysis For Roche

What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.

 Returns Oct 2022
MTD [1]		 2022
YTD [1]		 2017-22
Total [2]
 RHHBY Return 1% -20% 44%
 S&P 500 Return 4% -22% 66%
 Trefis Multi-Strategy Portfolio 3% -24% 201%

[1] Month-to-date and year-to-date as of 10/19/2022
[2] Cumulative total returns since the end of 2016

 

Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates